Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Hematology

Why Is Aspirin Stopped in ET With Very High Platelets?

At a Glance

In essential thrombocythemia, an extremely high platelet count can consume the most effective von Willebrand factor proteins and cause acquired von Willebrand syndrome. Aspirin can further weaken the platelet plug, so doctors may pause it after testing bleeding risk.

It can be incredibly confusing to have Essential Thrombocythemia (ET), a condition known for causing blood clots, and be told to stop taking aspirin. The reason is a complication called Acquired von Willebrand Syndrome (AVWS). When your platelet count gets extremely high, your body’s normal clotting proteins can become depleted. This doesn’t completely remove your risk of blood clots, but it introduces a new, serious risk of bleeding [1]. Aspirin is an antiplatelet medicine that makes platelets less sticky; taking it when you already have AVWS can tip the balance and dangerously worsen your bleeding risk [2][3].

How High Platelets Cause AVWS

Think of von Willebrand factor (VWF) as the “glue” that helps platelets stick together to form a protective plug when you are bleeding. The most effective pieces of this glue are large structures called high-molecular-weight multimers.

When your platelet count becomes excessively high (a state called extreme thrombocytosis), the sheer number of platelets circulating in your bloodstream causes problems. These excessive platelets latch onto the VWF protein, causing the crucial high-molecular-weight multimers to break down and be rapidly consumed [1][4].

Because your body uses up its best clotting glue faster than it can replace it, the initial formation of a platelet plug becomes less effective [5]. This creates a bleeding disorder that mimics an inherited condition called von Willebrand disease. Because it is caused by high platelets rather than inherited genetics, it is called an acquired syndrome [1][6].

Balancing Clotting and Bleeding Risks

Your hematologist manages ET by constantly balancing your risk of thrombosis (clotting) against your risk of bleeding. Platelet counts are commonly used as triggers to evaluate these risks, though they are guidelines rather than absolute rules:

  • Routine ET Management: Many ET patients take low-dose aspirin to reduce the risk of heart attacks, strokes, and blood clots. However, this is always an individualized decision based on age, cardiovascular risk, prior clots, and specific genetic mutations [7].
  • Approaching 1,000 × 10^9/L (about 1 million/µL): Guidelines recommend that doctors screen you for AVWS before starting or continuing aspirin [2][8]. Taking antiplatelet medicines when your von Willebrand factor is depleted can severely worsen bleeding [3].
  • Approaching 1,500 × 10^9/L (about 1.5 million/µL): The risk of AVWS-related bleeding becomes much higher, and doctors often consider initiating medications to actively lower the platelet count [9].

These thresholds do not mean you will definitively bleed or clot at a certain number. Some patients experience AVWS with platelet counts below 1 million, while others with extreme counts do not develop bleeding issues [6][5]. Your specific mutation also matters; for example, in certain low-risk patients, having a CALR mutation is associated with a higher bleeding risk when taking aspirin [7][10].

How AVWS is Tested and Treated

If your platelet count is very high, your doctor will likely run specialized blood tests [11][12]. You might hear them discuss:

  • VWF Antigen: Measures the total amount of VWF protein in your blood.
  • VWF Activity: Measures how well the VWF “glue” is actually working.
  • Multimer Analysis: Checks if the large, most effective pieces of VWF are missing.

If you have AVWS, the primary long-term treatment focuses on the root cause by lowering your platelet count. Cytoreductive therapies (medicines that reduce the excessive production of blood cells, like hydroxyurea or pegylated interferon) lower your platelet count and stop the rapid consumption of your VWF glue [4][13]. For severe, active bleeding or before an urgent surgery, specialists may use emergency hemostatic treatments like desmopressin, VWF-containing concentrates, or rapid mechanical platelet removal (plateletpheresis) [14][15].

Once your platelet counts are lowered by cytoreductive medication, your doctor will repeat VWF tests to confirm if your levels have recovered. Never stop or restart aspirin on your own—especially if it was prescribed for a previous heart attack, stroke, or stent—until your doctor confirms it is safe [4]. Also, avoid other medications that increase bleeding risk, such as NSAIDs (ibuprofen, naproxen) or certain supplements, unless explicitly approved by your care team.

When to Seek Emergency Care

Because you are managing both bleeding and clotting risks simultaneously, seek immediate emergency medical care (do not wait for a routine appointment) if you experience:

  • Signs of severe bleeding: Bleeding that will not stop, black or bloody stools, vomiting or coughing up blood, blood in your urine, unusually heavy menstrual bleeding, severe or sudden headache, or fainting.
  • Signs of a blood clot: Chest pain, sudden shortness of breath, sudden weakness or numbness (especially on one side of the face or body), difficulty speaking, or a new, painful, swollen leg.

Common questions in this guide

Why might my doctor stop aspirin if essential thrombocythemia raises my clot risk?
When the platelet count becomes extremely high, platelets can use up the largest, most effective forms of von Willebrand factor, a protein that helps stop bleeding. This can cause acquired von Willebrand syndrome, and aspirin may further impair platelet function, so a doctor may pause it after weighing both risks.
What platelet count makes aspirin unsafe in essential thrombocythemia?
A count approaching 1,000 × 10^9/L, or about 1 million/µL, commonly prompts testing for acquired von Willebrand syndrome before aspirin is started or continued. Around 1,500 × 10^9/L, or about 1.5 million/µL, bleeding risk is often higher and treatment to lower platelets may be considered, but no single count determines safety for everyone.
How do doctors test for acquired von Willebrand syndrome?
Blood testing may measure the amount of von Willebrand factor, how well it works, and whether the largest forms are present. These results, together with your platelet count and bleeding history, help your hematologist decide whether aspirin is appropriate.
How is bleeding risk from very high platelets treated?
The main approach is to lower the platelet count with cytoreductive medicines such as hydroxyurea or pegylated interferon. For severe bleeding or urgent surgery, specialists may use desmopressin, von Willebrand factor-containing concentrates, or plateletpheresis.
When can I restart aspirin after it is paused?
Do not restart or stop aspirin on your own. Your hematologist should review repeat von Willebrand factor tests, platelet counts, bleeding symptoms, and why aspirin was prescribed; people taking it for a prior heart attack, stroke, or stent may need coordination with the prescribing clinician.
What symptoms require emergency care with essential thrombocythemia and very high platelets?
Seek emergency help for bleeding that will not stop, black or bloody stools, vomiting or coughing blood, blood in the urine, fainting, or unusually heavy menstrual bleeding. Chest pain, sudden shortness of breath, one-sided weakness or numbness, trouble speaking, or a new painful swollen leg can signal a blood clot and also require immediate care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What were the specific results of my VWF antigen, VWF activity, and multimer tests?
  2. 2.At what specific platelet count or VWF activity level do you prefer to pause or resume my antiplatelet therapy?
  3. 3.Which over-the-counter pain relievers and supplements are safe for me to take while my bleeding risk is elevated?
  4. 4.How does my specific genetic mutation (such as CALR or JAK2) factor into my personalized bleeding and clotting risks?
  5. 5.What is the plan and timeline for repeating my blood work to see if my VWF levels have recovered?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Bleeding Complications in JAK2-Variant Essential Thrombocythemia: A Revisit in 2025.

    Gurumurthy G, Gurumurthy S, Somervaille TCP, et al.

    EJHaem 2025; (6(4)):e70088 doi:10.1002/jha2.70088.

    PMID: 40625825
  2. 2

    Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.

    Tefferi A, Barbui T

    American journal of hematology 2015; (90(2)):162-73 doi:10.1002/ajh.23895.

    PMID: 25611051
  3. 3

    Aspirin in essential thrombocythemia. For whom? What formulation? What regimen?

    Cattaneo M

    Haematologica 2023; (108(6)):1487-1499 doi:10.3324/haematol.2022.281388.

    PMID: 36632735
  4. 4

    Increased cleavage of von Willebrand factor by ADAMTS13 may contribute strongly to acquired von Willebrand syndrome development in patients with essential thrombocythemia.

    Kubo M, Sakai K, Hayakawa M, et al.

    Journal of thrombosis and haemostasis : JTH 2022; (20(7)):1589-1598 doi:10.1111/jth.15717.

    PMID: 35352474
  5. 5

    Philadelphia-negative myeloproliferative neoplasms and acquired von Willebrand syndrome: only pertinent at diagnosis?

    Lemarié F, Picard J, Galinat H, et al.

    Research and practice in thrombosis and haemostasis 2026; (10(5)):106858 doi:10.1016/j.rpth.2026.106858.

    PMID: 42576955
  6. 6

    Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera.

    Rottenstreich A, Kleinstern G, Krichevsky S, et al.

    European journal of internal medicine 2017; (41()):49-54 doi:10.1016/j.ejim.2016.11.011.

    PMID: 27919526
  7. 7

    Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

    Alvarez-Larrán A, Pereira A, Guglielmelli P, et al.

    Haematologica 2016; (101(8)):926-31 doi:10.3324/haematol.2016.146654.

    PMID: 27175028
  8. 8

    Do we need antiplatelet therapy in thrombocytosis? Contra. Proposal for an individualized risk-adapted treatment.

    Scharf RE

    Hamostaseologie 2016; (36(4)):241-260 doi:10.5482/HAMO-16-06-0016.

    PMID: 27414763
  9. 9

    Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet.

    Alvarez-Larrán A, Sant'Antonio E, Harrison C, et al.

    The Lancet. Haematology 2021; (8(9)):e658-e665 doi:10.1016/S2352-3026(21)00204-0.

    PMID: 34450103
  10. 10

    Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature.

    Nicol C, Lacut K, Pan-Petesch B, et al.

    Thrombosis and haemostasis 2021; (121(5)):553-564 doi:10.1055/s-0040-1720979.

    PMID: 33186994
  11. 11

    Evaluation of different diagnostic tools for detection of acquired von Willebrand syndrome in patients with polycythemia vera or essential thrombocythemia.

    Janjetovic S, Rolling CC, Budde U, et al.

    Thrombosis research 2022; (218()):35-43 doi:10.1016/j.thromres.2022.08.002.

    PMID: 35988442
  12. 12

    A Case of Acquired von Willebrand Disease Secondary to Myeloproliferative Neoplasm.

    Sasi S, Yassin MA, Fadul AM

    Case reports in oncology 2020; (13(2)):733-737 doi:10.1159/000507883.

    PMID: 32774267
  13. 13

    Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.

    Tefferi A, Barbui T

    American journal of hematology 2017; (92(1)):94-108 doi:10.1002/ajh.24607.

    PMID: 27991718
  14. 14

    Thrombocytapheresis for acquired von Willebrand syndrome in a patient with essential thrombocythemia and recent multivisceral transplantation.

    Oyedeji O, Sheqwara J, Onwubiko I, et al.

    Transfusion 2021; (61(11)):3277-3280 doi:10.1111/trf.16682.

    PMID: 34569071
  15. 15

    Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome.

    Kogan L, Price R, Kotchetkov R

    Frontiers in oncology 2024; (14()):1326209 doi:10.3389/fonc.2024.1326209.

    PMID: 38361779

This page explains why aspirin may be paused in essential thrombocythemia for informational purposes only and does not constitute medical advice. Do not stop or restart aspirin or other medicines without guidance from your hematologist and prescribing clinician.

Get notified when new evidence is published on Essential thrombocythemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.